CORRESPONDENCE

Clinical Practice Guideline: The Diagnosis and Treatment of Hepatocellular Carcinoma

by Prof. Dr. med. Nisar P. Malek, Dr. med. Sebastian Schmidt, Petra Huber, Prof. Dr. med. Michael P. Manns, and Prof. Dr. med. Tim F. Greten in issue 7/2014

SIRT Was Given Short Shift

The acronym SIRT stands for selective internal radiation therapy. At the present time, 19 completed studies and 20 ongoing studies are registered in ClinicalTrials.gov. Three of the studies are randomized multicenter phase III studies (SORAMIC, SIRveNIB, SARAH) at stages Child-Pugh A–B, whose follow-up results are expected for 2015–2017. The 5th SIRT symposium (the 5th European Multidisciplinary Symposium on Liver-Directed Cancer Therapy using ⁹⁰Y Microspheres) yielded the following insights regarding SIRT. SIRT was found to be the best therapeutic option in the setting of large tumors and portal vein invasion, since TACE had substantially more adverse effects and was much less effective. Furthermore, SIRT is being discussed as the first-line therapeutic approach for the purpose of downsizing HCC, in order to facilitate resectability. The data of the London based oncologist H Wasan, on the therapeutic effectiveness and cost effectiveness of SIRT, are interesting. Compared with chemoembolization, SIRT is less toxic, and the costs/QALY, which are reported to be €30 000–40 000, were found to be lower in one third of cases. By contrast, the costs/QALY of systemic therapy amount to €182 000 (cetuximab), €105 000 (bevacizumab), €71 000 (regorafenib), and €90 000 (sorafenib). Quality of life data after treatment are more favorable for SIRT than for TACE ($p = 0.019$), the time to progression is 8.4 months for TACE and 13.3 months for SIRT. The overall response rate for SIRT was reported to be 44–91%. These findings, which are also available for other tumor entities (1–3), justify cautious optimism regarding the expected study results and the effect in terms of the future importance of radioembolization in guidelines.

DOI: 10.3238/arztebl.2014.0464a

Prof. Dr. med. Peter Schneider

Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Schneider_P@ukw.de

REFERENCES

1. Salem R, Lewandowski RJ, Gates VL et al.: Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology: Research reporting standards for radioembolization of hepatic malignancies. *J Vasc Interv Radiol* 2011; 22: 265–78.
2. Sangro B, Carpanese L, Cianni R et al.: European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY): Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. *Hepatology* 2011; 54: 868–78.
3. Golfieri R, Bilbao JL, Carpanese L et al.: European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. *J Hepatol* 2013; 59: 753–61.
4. Malek NP, Schmidt S, Huber P, et al.: Clinical practice guideline: The diagnosis and treatment of hepatocellular carcinoma. *Dtsch Arztebl Int* 2014; 111: 101–6.

Conflict of interest statement

The author declares that no conflict of interest exists.

In Reply

SIRT does indeed constitute a new therapeutic option for the local treatment of advanced HCC at the intermediate stage. The 2013 guideline from the German Society for Digestive and Metabolic Diseases (Deutsche Gesellschaft für Verdauungs- und Stoffwechselerkrankungen, DGVS) recommended further investigation of this method, especially compared with transarterial chemotherapy (TACE), which is well established and has been evaluated in clinical studies. Currently, only few studies exist that undertook a direct comparison of these methods among themselves or in combination with sorafenib. Salem and colleagues showed that in 291 patients who had been treated with yttrium microspheres, liver function and the presence of portal vein thrombosis were the most important parameters for survival. An advanced study (Salem et al, 2011) showed in a comparison of SIRT and TACE a longer time to progression in the SIRT group (13.3 months vs 8.4 months), however, the difference in median survival between the two groups did not reach significance (20.5 months vs 17.5 months). Furthermore, it became obvious that more than 1000 patients would have had to have been recruited into the study in order to show a significant difference. In future this will be realized only by conducting large multicenter studies. We live in hope that the value of SIRT for the treatment of diffuse tumors and in portal vein thrombosis will be confirmed in appropriate studies. A comparison of the treatment costs for SIRT and for newer medications (sorafenib, avastin, etc.) is currently not the main issue, as palliative drug treatment is employed only in patients who are not eligible for locoregional treatment.

DOI: 10.3238/arztebl.2014.0464b

Prof. Dr. med. Nisar P. Malek, Dr. med. Sebastian Schmidt, Petra Huber

Prof. Dr. med. Michael P. Manns, Prof. Dr. med. Tim F. Greten

Medizinische Klinik 1, Universitätsklinikum Tübingen

Nisar.Malek@med.uni-tuebingen.de

REFERENCES

1. Salem R, Lewandowski RJ, Gates VL et al.: Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology: Research reporting standards for radioembolization of hepatic malignancies. *J Vasc Interv Radiol* 2011; 22: 265–78.
2. Sangro B, Carpanese L, Cianni R et al.: European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY): Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. *Hepatology* 2011; 54: 868–78.
3. Golfieri R, Bilbao JL, Carpanese L et al.: European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. *J Hepatol* 2013; 59: 753–61.
4. Malek NP, Schmidt S, Huber P, et al.: Clinical practice guideline: The diagnosis and treatment of hepatocellular carcinoma. *Dtsch Arztebl Int* 2014; 111: 101–6.

Conflict of interest statement

Prof. Malek has received payments for lectures from Bayer and consultation fees from Lilly.

Prof. Manns has received payments from Boehringer Ingelheim and BMS for his activities as advisory board member. He has benefited from third-party funding of studies by Bayer, Boehringer Ingelheim, BMS, Novartis, Pfizer, and Transgene.

The remaining authors declare that they have no conflicts of interest.